Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies
Summary
The prognosis of patients with relapsed and/or refractory T-cell hematologic malignancies is poor due to lacking sufficient treatment.Anti-CD(cluster of differentiation antigen)19 CAR(chimeric antigen receptor)-T cell therapies are efficient for patients with B-cell hematologic malignancies. As for T-cell hematologic malignancies, CD7 is a promising target expressed on most malignant T cells. The outcome of CD-7 CAR-T cell therapy pre-clinical experiments is cheerful.however, how to select the functional T cells from the malignant T cells is a challenge. In addition to this, auto-CAR-T cell therapy is not affordable for the majority of patients. Using T cells aphesis from healthy donors edited to avoid rejection of the host as the material of anti-CD7 universal CAR-T cells could be accessible and affordable, which is adapted for patients with CD7+ relapsed and/or refractory T/NK-cell hematologic malignancies.
Timeline
- Start
- 2021-03-01
- Primary completion
- 2022-06-01
- Completion
- 2023-06-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD7 UCAR-T cells | Cell therapy | 1e+07 cells/kg | — |
| Subject | CD7 UCAR-T cells | Cell therapy | 3e+07 cells/kg | — |
| Subject | CD7 UCAR-T cells | Cell therapy | 5e+07 cells/kg | — |
| Background | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Background | Fludarabine | Small molecule | 30 mg/m2 | — |
| Background | Melphalan | Small molecule | 50 mg/m2 | — |
| Background | Melphalan | Small molecule | 70 mg/m2 | — |